TGF-β Signaling Pathway Holds Key to Targeted Cancer Therapy
Research conducted at the Affiliated Hospital of Qingdao University in Shandong, People's Republic of China, has highlighted the complex role of transforming growth factor-beta (TGF-β) in cancer and fibrosis. The study reveals that TGF-β has opposing effects on fibrosis and cancer at different stages of these diseases. Under pathological conditions, overexpression of TGF-β can lead to the formation of cancer-associated fibroblasts and extracellular matrix deposition, ultimately resulting in fibrotic disease or cancer. The researchers suggest that therapies targeting TGF-β signaling may be a promising strategy for treating these diseases.
Key Takeaways:
- TGF-β has complex roles in fibrosis and cancer, with opposing effects at different stages of these diseases.
- Overexpression of TGF-β leads to epithelial-mesenchymal transition, deposition of extracellular matrix, and formation of cancer-associated fibroblasts.
- TGF-β targets fibroblasts, epithelial cells, and immune cells, while fibrosis and cancer are the most common TGF-β-associated diseases.
- Targeted TGF-β therapy appears to be a promising strategy, with therapies including antisense oligonucleotides, monoclonal antibodies, and ligand traps.
- Preclinical and clinical studies have investigated therapies targeting TGF-β, but development of targeted TGF-β therapy has been hindered by systemic cytotoxicity.
- The study highlights the importance of understanding the molecular mechanisms of TGF-β signaling in cancer and fibrosis.
Statistics:
- Cancer and fibrosis are the most common TGF-β-associated diseases, accounting for significant morbidity and mortality worldwide.
- TGF-β has a complex role in fibrosis and cancer, with multiple targets, including fibroblasts, epithelial cells, and immune cells.
- Research has identified TGF-β as a critical component of the fibrotic and cancerous process, with overexpression leading to disease progression.
- Targeted TGF-β therapy has shown promise in preclinical and clinical studies, with therapies including antisense oligonucleotides, monoclonal antibodies, and ligand traps.
Sources:
- "Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis." Frontiers in Oncology, 2025, 15.
- Frontiers in Oncology: http://www.frontiersin.org/oncology
- Frontiers Media S.A: publisher of Frontiers in Oncology